The Impact of Antitumor Treatment on Cancer Patients with COVID-19: A Systematic Review and Meta-Analysis
Abstract
Background: Cancer is a chronic disease that can cause various complications, decrease the immune system, reduce quality of life, and even lead to death. In addition, the COVID-19 pandemic in various countries has had a significant adverse impact on patients. This study analyzed the impact of various antitumor treatments on cancer patients with COVID-19.
Methods: This meta-analysis was conducted according to the PRISMA – P pathway. Source searches were conducted in PubMed, Cochrane Library, Research Gate, and Science Direct in cancer patients with COVID-19 receiving various types of antitumor treatment. Analysis was performed using RevMan V.5.3 software with the outcome of mortality rate and severe COVID-19.
Results: Twenty-five observational studies met the inclusion criteria with a total of 21,940 patients. There was no significant difference in mortality rate (OR 1.08, 95% CI 0.99 – 1.18, p = 0.09), but there was a significant difference in severe COVID-19 (OR 1.19, 95% CI 1.02 – 1.39, p = 0.02). Immunotherapy provided the most significant worsening of both mortality rate (OR 1.39, 95% CI 1.17 – 1.64, p = 0.0001) and severe COVID-19 (OR 1.82, 95% CI 1.23 – 2.71, p = 0.003). There were no significant differences in other antitumor treatments.
Conclusions: Antitumor treatment does not have a significant impact on mortality rate, but has a significant impact on worsening the degree of COVID-19. Among all the antitumor therapies that provide the highest potential for worsening is immunotherapy.
Keywords
DOI: 10.33371/ijoc.v18i3.1158
Article Metrics
Abstract View: 178, 
PDF Download: 84
References
WHO International Agency for Research on Cancer. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 [Internet]. Lyon: IARC; 2018 [cited 2023 Mar 29]. Available from: https://www.iarc.who.int/wp-content/uploads/2018/09/pr263_E.pdf.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. The Lancet. 2020;395(10241):1907–18.
Zong Z, Wei Y, Ren J, et al. The intersection of covid-19 and cancer: Signaling Pathways and Treatment Implications. Molecular Cancer. 2021;20(1).
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of Oncology. 2020;31(7):894–901.
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720.
Bora VR, Patel BM. The Deadly Duo of COVID-19 and Cancer! Front Mol Biosci. 2021 Apr 12;8:643004.
Elkrief A, Wu JT, Jani C, et al. Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discov. 2022 Feb;12(2):303-330.
Moher D, Shamseer L, Clarke M, e al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4(1):1.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
Asghar K, Abu Bakar M, Ashfaq S, et al. COVID-19 in cancer patients with diabetes in Pakistan: Clinical features and management. Front Oncol. 2022 Aug 18;12:922579.
Assaad S, Avrillon V, Fournier ML, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020 Aug;135:251-259.
Bakouny Z, Labaki C, Grover P, et al. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncol. 2023;9(1):128–134.
García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020 Oct 8;13(1):133.
Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 Jun;32(6):787-800.
Gupta A, Desai N, Sanjeev, et al. Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India. Ann Hematol. 2022 Jan;101(1):69-79.
Hermel DJ, Cham J, Spierling Bagsic SR, et al. An observational study of hospitalized COVID-19 patients with cancer in San Diego county. Future Oncol. 2022 Feb;18(6):719-725.
Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020 Oct 20;38(30):3538-3546.
Lara OD, O’Cearbhaill RE, Smith MJ, et al. Covid‐19 outcomes of patients with gynecologic cancer in New York City. Cancer. 2020;126(19):4294–303.
Lara OD, Smith M, Wang Y, et al. COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic. Gynecol Oncol. 2022 Feb;164(2):304-310.
Lee LYW, Cazier JB, Angelis V, et al. Covid-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. The Lancet. 2020;395(10241):1919–26.
Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-941.
Mirgh SP, Gokarn A, Rajendra A, et al. Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India. Cancer Med. 2021 Dec;10(24):8777-8788.
Mousavi SA, Rostami T, Kiumarsi A, et al. COVID-19 and cancer: A comparative case series. Cancer Treat Res Commun. 2021;27:100339.
Nakamura S, Kanemasa Y, Atsuta Y, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. Int J Clin Oncol. 2021 Mar;26(3):485-493.
Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol. 2020 Dec;22(12):2364-2368.
Russell B, Moss C, Papa S, et al. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Front Oncol. 2020 Jul 22;10:1279.
Sadeghi A, Dooghaie Moghadam A, Eslami P, et al. The characteristics of cancerous patients infected with COVID-19 in hospital setting. Acta Biomed. 2020 Nov 10;91(4):e2020145.
Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020 Nov;105(5):597-607.
Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol. 2020 Jul;16(20):1425-1432.
Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 Jul;21(7):893-903.
Yang F, Shi S, Zhu J, et al. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020 Oct;92(10):2067-2073.
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020 Jul;21(7):904-913.
Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (Covid‐19) infection in 107 patients with cancer from Wuhan, China. Cancer. 2020;126(17):4023–31.
Patel R, Park J, Shah A, Saif MW. Covid-19 and cancer patients [Internet]. Cancer medicine journal. U.S. National Library of Medicine; 2020 [cited 2023Apr5]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219960/
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018 Feb;18(2):91-104.
Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017 Dec;64(12).
Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:557.
Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10:183–93.
Liu H, Yang D, Chen X, et al. The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis. Cancer Med. 2021 Feb;10(3):1043-1056.
Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 Nov;21(11):799-820.
Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022 Oct;42(10):913-936.
Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011 Jan;135(1):55-62.
Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct;204:115209.
Uddin MH, Zonder JA, Azmi AS. Exportin 1 inhibition as antiviral therapy. Drug Discov Today. 2020 Oct;25(10):1775-1781.
Li JJ. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. iScience. 2020 Jun 26;23(6):101215.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
